NadineJacksonMcClearyMD
Hematology • Boston, MAMyeloproliferative Disorder Hematology-Oncology
Instructor in Medicine, Dana-Farber Cancer Institute
Dr. McCleary is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
450 Brookline Ave
Dana-Farber Cancer Institu
Boston, MA 02115- Is this information wrong?
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2006 - 2009
Johns Hopkins UniversityResidency, Internal Medicine, 2003 - 2006- Johns Hopkins University School of MedicineClass of 2002
Certifications & Licensure
FL State Medical License 2022 - Present
MA State Medical License 2007 - 2025
CT State Medical License 2022 - 2024- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Routine Evaluation of the Social Determinants of Health in Oncology: User-centered Resource Coordination and Engagement Start of enrollment: 2021 May 17
Roles: Principal Investigator, Contact
- SURGE: Supporting UnderRepresented Minorities in Genomics-based Cancer Trial Enrollment (Intervention) Start of enrollment: 2023 Apr 03
Roles: Contact, Principal Investigator, Sponsor-Investigator
- Resilience and Equity in Aging, Cancer, and Health (REACH) Start of enrollment: 2022 Jan 18
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- Social Determinants of Health Needs and Health-related Quality of Life Among Surgical Patients: A Retrospective Analysis of 8512 Patients.Sri Harshini Malapati, Maria O Edelen, Manraj N Kaur, Chengbo Zeng, Gezzer Ortega, Harrison Hubbell, Allison S Bryant, Rachel C Sisodia, Andrea L Pusic, Meyers, P., Mc...> ;Annals of Surgery. 2024 Mar 1
- Biomarkers of pembrolizumab efficacy in advanced anal squamous cell carcinoma: analysis of a phase II clinical trial and a cohort of long-term responders.Huffman, B., Singh, H., Ali, L., Horick, N., Wang, S., Hoffman, M., Metayer, K., Murray, S., Bird, A., Abrams, T., Biller, L., Chan, J., Meyerhardt, J., McCleary, N., ...> ;Journal for Immunotherapy of Cancer. 2024 Jan 25
- Strategies for Implementing an Electronic Patient-Reported Outcomes-Based Symptom Management Program Across Six Cancer Centers.Hassett, M., Dias, S., Cronin, C., Schrag, D., McCleary, N., Simpson, J., Poirier-Shelton, T., Bian, J., Reich, J., Dizon, D., Begnoche, M., Jenkins, H., Tasker, L., W...> ;Research Square. 2024 Jan 24
- Join now to see all
Press Mentions
SURGE: Supporting UnderRepresented Minorities in Genomics-Based Cancer Trial Enrollment (Intervention)May 16th, 2022- UA College of Medicine Selected for an Internship ProgramJuly 20th, 2021
Mom Diagnosed with Stage 4 Cancer After Pregnancy Encourages Women to Trust Their InstinctsFebruary 21st, 2020
Hospital Affiliations
Dana-Farber Cancer InstituteBoston, Massachusetts
Brigham and Women's HospitalBoston, Massachusetts
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
